SOHO 2018 | CAR T across hematological malignancies: trials to watch
John Rossi
Axicabtagene ciloleucel, an anti-CD19 CAR T-cell product, has shown impressive efficacy in diffuse large B-cell lymphoma already. In this video, recorded at the 2018 Society of Hematologic Oncology (SOHO) Annual Meeting held in Houston, TX, John Rossi, MS, from Kite Pharma Inc., Santa Monica, CA, highlights clinical trials in the ZUMA series which are targeting a variety of B-cell malignancies and leukemias with axicabtagene ciloleucel. He also discusses KITE 585, an anti-BCMA CAR T product which is being tested at Phase 1 (NCT03318861) in multiple myeloma.
Related videos
Venetoclax-resistance conferring mutation in CLL identified
Piers Blombery
Venetoclax monotherapy for relapsed/refractory Waldenström’s macroglobulinemia
Jorge Castillo
Waldenström's PFS unaffected by ibrutinib dose reduction, for now
Jorge Castillo
Anti-CD19 CAR T-cell therapy in combination with ibrutinib for CLL/SLL
Saar Gill
An exciting era for CAR T-cell therapy
Mohamad Mohty
